Australia's First
TB-500
Subcutaneous Pen



What is TB-500?

TB-500 (Thymosin β-4 fragment) is a synthetic section of the thymosin β-4 protein, which regulates actin formation and cell migration critical to wound and tissue recovery.

TB-500 is prescription-only in Australia and supplied as sterile compounded preparations following consultation with a registered clinician.

What TB-500 Is Being Studied For?

Current research is exploring TB-500 in contexts such as:

Cell migration and cytoskeletal dynamics: Laboratory research examining actin-related pathways involved in cellular movement and structural organisation.
Tissue biology: Preclinical investigations into how TB-500 may interact with processes involved in tissue maintenance and remodelling.
Vascular response and perfusion: Early studies assessing effects on angiogenic signalling and local circulation.
Inflammatory balance: Experimental models evaluating interactions with inflammatory signalling pathways.

These investigations are preliminary. TB-500 has not been approved by the TGA for the prevention, treatment, or cure of any condition.

How It's Dispensed?

When prescribed, the TB-500 formulation is compounded by an Australian-registered pharmacy and dispensed under pharmacist supervision.

Concentration:TB-500 (3 mg/mL)
Volume: 3 mL pre-filled subcutaneous pen
Preservative system: Formulated in accordance with pharmacy sterility and stability standards
Temperature control: Shipped in insulated packaging with cold packs to maintain integrity during transport

Storage & Handling

Keep refrigerated as directed by the dispensing pharmacy.
Do not freeze or expose to excessive heat.
If ice packs melt during transit, product integrity remains unaffected within the advised shipping window.
Always follow the storage and handling guidance supplied with your prescription.

Usage & Administration

Administration technique, dose volume, and frequency are determined individually by the prescribing clinician.

Follow all instructions printed on the pharmacy label. Do not self-administer unless you have received appropriate training and clinical clearance.

Typical practitioner-directed use may include:
Route: Subcutaneous injection via pre-filled TB-500 pen.
Injection site: Commonly administered into the lower abdomen or outer thigh for systemic distribution, unless a different strategy is advised.
Pattern: Systemic micro-dosing aimed at supporting connective tissue, soft-tissue recovery and broader repair signalling rather than a single focal point.
Cycle: Frequently structured as five days on and two days off to align with TB-500’s pharmacokinetics and allow periodic receptor reset while maintaining ongoing peptide exposure.
Technique: Clean the skin with an alcohol swab, inject as directed, and dispose of the needle safely after each dose.
Rotation: Alternate injection locations (left/right abdomen or thighs) to reduce irritation and support consistent absorption.

All dosing parameters (including total weekly exposure, cycle length, and overall course duration) are determined by the prescribing clinician according to recovery goals, training load, and individual tolerance.

Safety & Precautions

Schedule 4 (Prescription-Only Medicines) must be prescribed and supervised by a registered healthcare professional.
Disclose all medical conditions, allergies, and concurrent medications before treatment.
Not recommended during pregnancy or breastfeeding unless specifically approved by a clinician.
Report any irritation or unexpected response to your prescriber or pharmacist.
Always store and administer as directed by the dispensing pharmacy.

Research Context

TB-500 remains an area of active scientific investigation. Laboratory and early clinical studies are not equivalent to established therapeutic outcomes in humans. Further controlled research is required to determine safety, effectiveness, and appropriate clinical application. All prescribing in Australia occurs under compounded, off-label frameworks within appropriate medical oversight.

Disclaimer

Educational content only; not medical advice.

TB-500 compounded preparations are not registered with the Therapeutic Goods Administration (TGA).

No claims of efficacy or therapeutic outcome are made.

All use requires individual consultation and prescription by a registered clinician.

Mobile IV Drip

TB-500 Australia

Prescription TB-500 Australia

Australian Compounded TB-500

Australian Compounded Prescription Peptides

TB-500 Pen

TB-500 Subcutaneous Pen

TB-500 Injection Pen

Tissue Recovery Support Peptide

Recovery Support Peptide

Restore TB-500

ExclusIV Disclaimer

By continuing, you acknowledge and agree to the following terms and conditions of ExclusIV by Mobile IV Drip:

1. Elective Wellness Services
All IV infusions and subcutaneous products offered through Mobile IV Drip are elective wellness services. They are not prescribed or promoted as medically necessary treatments and are designed to support general wellness and vitality.

2. No Public Advertising
The information displayed in this section is provided privately on request and does not constitute public advertising.

3. No Medical or Therapeutic Claims
No statements here should be interpreted as claims of therapeutic benefit. Services and compounded formulations are not a substitute for professional medical advice, prescribed medication, or conventional treatment.

4. Practitioner Review Required
Before any compounded or prescription-only product is supplied, clients are required to complete medical intake and be reviewed by an authorised prescriber and/or nurse practitioner, and obtain a prescription where required.

5. Pricing
Pricing shown is indicative only and may change following clinical assessment, prescription requirements, or compounding variables. Final costs are confirmed after prescriber approval.

6. Voluntary Request
You confirm you are voluntarily requesting this information for personal education, and that access does not guarantee suitability for every option listed.

7. Privacy
Any information you provide may be used to communicate about consultations, prescriptions or updates, with opt-out available.

By selecting “I want ExclusIV access”, you confirm you have read and understood the above.